Results 51 to 60 of about 1,494 (190)
Targeted diphtheria toxin to treat BPDCN
Blood, 2014 In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).
openaire +3 more sources
CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm
, 2022 SIMPLE SUMMARY: Until recently, there were no approved therapies for the aggressive blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN). Survival for patients diagnosed with BPDCN is under two years, and improved treatments are needed.
Naveen Pemmaraju +9 more
core +1 more source
HemaSphere, 2023 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematological malignancy characterized by recurrent skin nodules, an aggressive clinical course with rapid involvement of hematological organs, and a poor prognosis with overall survival.
Livio Pagano +10 more
doaj +1 more source
Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting [PDF]
Journal of Immunotherapy and Precision OncologyBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options.
Prajwal Dhakal +5 more
doaj +1 more source
eJHaem, 2022 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we
Jad Sibai +4 more
doaj +1 more source
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN
Biology of Blood and Marrow Transplantation, 2020 Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy arising from plasmacytoid dendritic cells. It commonly presents as skin lesions with or without bone marrow, lymph node or systemic involvement. Limited retrospective data have shown durable remissions after allogeneic (allo) hematopoietic cell
Muzaffar H. Qazilbash +12 more
openaire +1 more source
Blood, 2015 Abstract Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive neoplasm for which there is still no current consensus on the best therapeutic approach. Most patients respond to intensive chemotherapy, but relapses are almost inevitable with median overall survival (OS) in the largest patient series ranging from 8 to 12 ...
Eve Poret +46 more
openaire +1 more source
Cutaneous involvement by myeloid leukaemias: challenging cases with important implications
Histopathology, EarlyView.Myeloid leukaemias and precursors involving the skin are often challenging to diagnose with varied and overlapping clinical and histopathologic features. Nonetheless, they are critical for pathologists to recognize and accurately classify. This review discusses the clinical, histopathological and genetic features of myelodysplasia cutis (A) and ...
Alexandra C. Hristov
wiley +1 more source
ICSH Guidance on Bone Marrow Examination and Reporting
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber +6 more
wiley +1 more source
Dermatopathology, 2022 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare tumor that affects elderly individuals and presents a poor prognosis. Skin is the most common site of involvement, accounting for 89% of the cases.
Phanitchanat Phusuphitchayanan +6 more
doaj +1 more source